Zobrazeno 1 - 10
of 10
pro vyhledávání: '"FASN Inhibitor TVB-2640"'
Autor:
Peter Schmid, Kathleen N. Moore, Andrew Brenner, Arthur E. Frankel, Gerald Steven Falchook, H. A. Burris, Katharine Grimmer, Juanita Lopez, George Kemble, EM Dean, J. R. Infante, William McCulloch, Erkut Borazanci, Steven J.M. Jones, Manish R. Patel, H.-T. Arkenau
Publikováno v:
Cancer Research. 77:P6-11
Introduction FASN inhibition is a novel approach to cancer treatment involving selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first-in-class, small molecule reversible inhibitor of FASN t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a44f3b152683468749656b9e0266a0c3
https://doi.org/10.1158/1538-7445.sabcs16-p6-11-09
https://doi.org/10.1158/1538-7445.sabcs16-p6-11-09
Autor:
Arthur E. Frankel, George Kemble, Peter Schmid, Howard A. Burris, Gerald Steven Falchook, Manish R. Patel, Hendrik-Tobias Arkenau, Kathleen N. Moore, Jeffrey R. Infante, Andrew Brenner, Suzanne F. Jones, William McCulloch, Juanita Lopez, Erkut Borazanci, Emma Dean
Publikováno v:
Cancer Research. 77:CT153-CT153
Introduction FASN inhibition causes selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first-in-class, small molecule reversible inhibitor of FASN that demonstrated in vivo antitumor effects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75252a6714fc4819b078cd8c44da580f
https://doi.org/10.1158/1538-7445.am2017-ct153
https://doi.org/10.1158/1538-7445.am2017-ct153
Autor:
Joanna Waszczuk, Marina Fridlib, Doug Buckley, William McCulloch, Richard Crowley, Marie O'Farrell, Claudia Rubio, Katharine Grimmer, Julie Lai, George Kemble, Richard Benn Abegania Ventura, Tim Heuer
Publikováno v:
Cancer Research. 76:LB-214
TVB-2640 is an oral, first-in-class, selective and reversible inhibitor of fatty acid synthase (FASN) in Phase 1 testing in solid tumor patients (study 3V2640-CLIN-002). FASN is a central mediator of neoplastic lipogenesis and uniquely catalyzes the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f83057e6e32f27edd75210ae9e587ca2
https://doi.org/10.1158/1538-7445.am2016-lb-214
https://doi.org/10.1158/1538-7445.am2016-lb-214
Autor:
Howard A. Burris, Hendrik-Tobias Arkenau, Peter Schmid, Erkut Borazanci, Arthur E. Frankel, Andrew Brenner, Emma Dean, Marie O'Farrell, Gerald Steven Falchook, George Kemble, Jeffrey R. Infante, Juanita Lopez, Shubham Pant, William McCulloch, Suzanne F. Jones, Manish R. Patel
Publikováno v:
Journal of Clinical Oncology. 34:2512-2512
2512Background: FASN inhibition is a novel approach to cancer treatment involving selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95b6aff772075e77ed9f2bf703054c02
https://doi.org/10.1200/jco.2016.34.15_suppl.2512
https://doi.org/10.1200/jco.2016.34.15_suppl.2512
Autor:
D. D. Von Hoff, M. Parsey, William McCulloch, J. R. Infante, Andrew Brenner, Valentina Zhukova-Harrill, C. Rubino, Manish R. Patel
Publikováno v:
European Journal of Cancer. 50:195-196
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a76531ae86ff9b44c4e408230337c05
https://doi.org/10.1016/s0959-8049(14)70724-5
https://doi.org/10.1016/s0959-8049(14)70724-5
Publikováno v:
Molecular Cancer Research. 14:A75-A75
Dysregulated expression of FASN is a central mediator of neoplastic lipogenesis. FASN catalyzes the production of palmitate, the building block of long chain fatty acids, providing a mechanism to convert glucose and other carbon sources into lipids n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e24498a3bd4ff51b940871f92e61113c
https://doi.org/10.1158/1557-3125.metca15-a75
https://doi.org/10.1158/1557-3125.metca15-a75
Autor:
Marie O'Farrell, Valentina Zhukova-Harrill, Hendrik-Tobias Arkenau, L. R. Molife, Lorraine Pelosof, C. Rubino, Shubham Pant, Jeffrey R. Infante, Manish R. Patel, Howard A. Burris, Mark Voskoboynik, William McCulloch, Suzanne F. Jones, Erkut Borazanci, Gerald Steven Falchook, George Kemble, Emma Dean, Andrew Brenner
Publikováno v:
Molecular Cancer Therapeutics. 14:A54-A54
Introduction FASN inhibition is a novel approach to cancer treatment involving the selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first-in-class, small-molecule reversible inhibitor of FA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d0e38637ec257d7e5294c53da35d9e0
https://doi.org/10.1158/1535-7163.targ-15-a54
https://doi.org/10.1158/1535-7163.targ-15-a54
Autor:
Timothy S. Heuer, Richard Crowley, C. Rubino, Marie O'Farrell, Doug Buckley, William McCulloch, George Kemble
Publikováno v:
Cancer Research. 75:2675-2675
TVB-2640 is a potent, reversible and selective fatty acid synthase (FASN) inhibitor currently in its first Phase 1 study (3V2640-CLIN-002) in solid tumor patients. This study includes biomarker assays for this first in class agent to assess pharmacod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bf2a4f26b473cbba50d388e67e1a6ff
https://doi.org/10.1158/1538-7445.am2015-2675
https://doi.org/10.1158/1538-7445.am2015-2675
Autor:
Daniel D. Von Hoff, William McCulloch, Manish Patel, Valentina Zhukova-Harrill, Suzanne F. Jones, Merdad Parsey, Andrew Brenner, George Kemble, Jeffrey R. Infante, Howard A. Burris
Publikováno v:
Cancer Research. 75:CT203-CT203
FASN inhibition is a novel approach to cancer treatment involving the selective disruption of palmitate biosynthesis that, in tumor cells, causes changes in cell signaling, sensitivity to chemotherapeutic agents, and apoptosis in addition to other ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25fa294f3c45ee1efce5ae19fc509781
https://doi.org/10.1158/1538-7445.am2015-ct203
https://doi.org/10.1158/1538-7445.am2015-ct203
Autor:
C. Rubino, William McCulloch, George Kemble, Suzanne F. Jones, Manish R. Patel, Howard A. Burris, Jeffrey R. Infante, Daniel D. Von Hoff, Valentina Zhukova-Harrill, Andrew Brenner
Publikováno v:
Journal of Clinical Oncology. 33:TPS2615-TPS2615
TPS2615 Background: FASN is a central mediator of neoplastic lipogenesis. It catalyzes the production of palmitate, the building block of long chain fatty acids needed to support cancer cell signal...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb49506a01418ef38e589e26cebc5018
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2615
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2615